56 results about "Local immunity" patented technology

A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host, and methods for making and using the same are provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis. The transgenes comprise two or more of the followinggenes: PD-L 1, HLAG or H2-M3, Cd47, Cd200, FASLG or Fasl, Ccl21 or Ccl21b, Mfge8, and Serpin B9 or Spi6.

Disclosed are an antigen-drug vehicle (AD vehicle) exerting a function of inducing the preferential and selective production of an antigen-specific secretory IgA antibody, local immunity or mucosal immunity; a method of inducing mucosal immunity, a mucosal vaccine and a preventive or a remedy for allergy using the above AD vehicle; and a transmucosal or transdermal DDS using the above vehicle.

The invention discloses application of 6-diazo-5-oxo-L-leucine in preparation of drugs for preventing and treating psoriasis, and relates to the technical field of medicine. Experimental comparisons discover that the skin thickening at the psoriasis lesion after DON metabolic intervention is obviously reduced, the infiltration of immune cells is reduced, and DON can effectively inhibit inflammatory local immune response; at the same time, DON alleviates the spleen swelling phenomenon of psoriasis, and also effectively inhibits the inflammatory immune response of psoriasis; and by detecting the expression of proinflammatory factors at the skin inflammation site of psoriasis, DON also inhibits the expression of such genes, and DON effectively alleviates the symptoms of psoriasis.

The purpose of the present invention is to provide a riemerella anatipestifer bacterial ghost vaccine loaded with polyinosinic acid-polycytidylic acid having interferon inducing activity and added with chitosan oligosaccharide as an adjuvant. According to the technical scheme, a temperature control expression vector is constructed and is electrotransformed into riemerella anatipestifer protoplast, positive clones are screened and then are subjected to bacterial amplification culture at a temperature of 28 DEG C, lysis gene expression is induced at a temperature of 42 DEG C, polylysine is added to continuously act when the OD600 is no longer be reduced so as to completely lyze the live bacteria, centrifugation is performed to separate the bacteria, the dried bacteria and a 6 mg / mL Poly I:C solution according to an equal ratio so as to make the Poly I:C be embedded into the bacterial ghosts, a 2% chitosan oligosaccharide aqueous solution is added, stirring is performed to form a uniform mixture, sub-packaging is performed into penicillin bottles, and freeze-drying is performed so as to obtain the novel riemerella anatipestifer bacterial ghost vaccine. According to the present invention, the prepared riemerella anatipestifer bacterial ghost vaccine is immunized through drinking water, such that the local immunity on the respiratory tract mucous membrane and the digestive tract mucous membrane can be irritated, the humoral immunity can be stimulated, and the protection effect on the human body is not different from the injection immunity.

The invention discloses a medicament for treating vaginitis and capable of preventing lactobacillus in a vagina from being killed. The pH value of the medicament is 2.5 to 6.5, and the medicament is prepared by mixing bamboo vinegar or / and wood vinegar with a matrix and water, wherein in percentage by weight, the bamboo vinegar or / and wood vinegar accounts for 2 to 50 percent of the weight of the medicament, and the matrix accounts for 0.1 to 35 percent of the weight of the medicament; the water accounts for the balance percentage of the weight of the medicament. An experiment shows that the medicament disclosed by the invention has a specific killing or suppressing effect on harmful pathogenic bacteria, but cannot kill or suppress probiotics and lactobacillus; the shortcoming that vaginitis is mainly treated with relevant medicaments such as antibiotic is overcome; the ecological environment of the vagina is well maintained, the vagina self-cleaning effect of the lactobacillus is developed, and local immunity of the vagina is enhanced; the medicament is expected to be an optimal medicament for treating the vaginitis and has a good clinical application prospect.

The present invention relates to a method for conversion preparation of a riemerella anatipestifer pre-bacterial ghost vaccine by using phage PhiX174 E gene and staphylococcal nuclease A gene, and an application method. According to the technical scheme, the phage PhiX174 E gene and the staphylococcal nuclease A gene are coupled to form the series coupling gene through the flexible coupling arm (Gly4Ser), a temperature control expression vector pBV-E-SN is further constructed, the pBV-E-SN is transformed into riemerella anatipestifer protoplast through electric shock conversion, the positive clones are screened and are subjected to bacterial amplification culture at a temperature of 28 DEG C, the bacteria are separated, a protection agent is added, and sub-packaging and freeze-drying are performed. According to the present invention, the prepared live bacterial vaccine is immunized through drinking water, such that the local immunity on the respiratory tract mucous membrane and the digestive tract mucous membrane can be irritated, and the humoral immunity can be stimulated.

Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) in other embodiments. Hydrogel carrier materials for delivery of ISV agents and are also described herein.

The present disclosure relates to parenteral nutrition formulations, including ready-to-use parenteral nutrition formulations which are reconstituted from multi-chamber containers and amino acid formulations. More particularly, the present disclosure is directed to formulations comprising butyrate derivatives, specifically arginine butyrate, for use with adult or pediatric patients. The disclosure further provides for methods of reducing or preventing systemic and local inflammation of patients receiving parenteral nutrition, and methods of maintaining or ameliorating their systemic immunity and local immunity, as well as the patients' gut barrier functions.